NASDAQ$AHCO
AdaptHealth Corp. · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
AdaptHealth achieved record revenue and adjusted EBITDA, driven by organic growth and strategic acquisitions.
AdaptHealth reported record revenue of $627.6 million, a 43% increase year-over-year. Adjusted EBITDA was $135.3 million, up 36% year-over-year. The company raised its full-year guidance, reflecting confidence in continued growth.
- Net revenue increased to $627.6 million, up 43% year-over-year.
- Adjusted EBITDA grew to $135.3 million, a 36% increase year-over-year.
- Net income was $13.9 million, compared to a net loss of $7.8 million in the prior year.
- The company raised its full-year 2021 net revenue guidance to $2.34 billion to $2.37 billion and adjusted EBITDA guidance to $518 million to $526 million.
Headline financials
Revenue & EPS history
AdaptHealth · Revenue · Quarterly
$653M
Forward guidance
AdaptHealth raised its full-year 2021 net revenue guidance to $2.34 billion to $2.37 billion and adjusted EBITDA guidance to $518 million to $526 million.
Tailwinds
- Net revenue guidance increased to $2.34B - $2.37B
- Adjusted EBITDA guidance increased to $518M - $526M
- Expect continued organic growth in core segments.
- Anticipate further benefits from recent acquisitions.
- Strong performance in Q3 2021 provides momentum for the rest of the year.
Headwinds
- Potential for supply chain disruptions to impact product availability.
- Uncertainty regarding the duration and impact of the COVID-19 pandemic.
- Increased competition in the home healthcare market.
- Changes in reimbursement policies could affect profitability.
- Integration risks associated with recent and future acquisitions.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+0.6%
Avg return
Earnings day
+1.4%
Avg return
5 days after
+1.6%
Avg return
30 days after
52%
16 / 31 earnings
Positive
+34.6%
Q4 2023
Best reaction
-27.9%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -10.0% | -13.4% | -25.6% | |
| Q4 2025 | -14.2% | -11.1% | +10.9% | |
| Q3 2025 | +17.2% | +4.5% | +3.2% | |
| Q1 2025 | +1.7% | -1.4% | +3.7% | |
| Q4 2024 | +24.4% | +33.1% | +24.4% | |
| Q3 2024 | +0.3% | -0.6% | -4.2% | |
| Q2 2024 | -17.2% | -14.1% | +4.6% | |
| Q1 2024 | -8.6% | -8.8% | +4.9% | |
| Q4 2023 | +34.6% | +37.9% | +50.9% | |
| Q3 2023 | -23.1% | -18.6% | -5.6% | |
| Q2 2023 | +11.1% | +4.4% | -19.8% | |
| Q1 2023 | -8.4% | -12.2% | -13.8% | |
| Q4 2022 | -27.9% | -27.9% | -40.6% | |
| Q3 2022 | -1.6% | +8.4% | +4.5% | |
| Q2 2022 | -8.9% | -8.2% | -25.7% | |
| Q1 2022 | +23.7% | +42.2% | +53.6% | |
| Q4 2021 | +4.1% | +2.3% | +2.8% | |
| Q3 2021 | -5.4% | -7.2% | -24.1% | |
| Q2 2021 | +16.4% | +13.4% | +12.3% | |
| Q1 2021 | -8.5% | -14.9% | -10.4% | |
| Q4 2020 | +2.1% | +12.4% | +21.7% | |
| Q3 2020 | +2.6% | +0.6% | +19.5% | |
| Q2 2020 | +13.9% | +18.0% | +7.0% | |
| Q1 2020 | +1.6% | +5.8% | +5.5% | |
| Q4 2019 | +1.8% | +1.4% | -7.7% | |
| Q3 2019 | -4.1% | -4.9% | -3.3% | |
| Q2 2019 | +0.0% | +0.0% | -0.6% | |
| Q1 2019 | +0.0% | +0.0% | +0.3% | |
| Q4 2018 | +0.6% | +0.7% | +1.3% | |
| Q3 2018 | +0.3% | +0.1% | +0.4% | |
| Q2 2018 | +0.0% | +0.3% | +0.1% | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro